May 2, 2018
Bloomberg Law
On May 1, 2018 a district court ruled in favor of Finnegan client Valeant Pharmaceuticals, ruling that defendants Mylan and Actavis were unable to prove a patent on Valeant's Relistor drug is invalid due to obviousness. The court said, "[t]he bottom line is that Defendants have pointed to no evidence that claim 8 was either an 'identified, predictable solution' or an 'anticipated success.'"
Award/Ranking
Managing IP Americas Awards 2024: Finnegan Shortlisted for Nine Awards, Including Firm of the Year
March 12, 2024
Commentary
February 29, 2024
Press Release
Finnegan Secures Another Patent Victory for BMW Group in the District of Delaware
February 27, 2024
Press Release
February 13, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.